CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration on Tuesday approved a supplemental new drug application by Roche for the combined use of its protease inhibitor Invirase with a booster dose of Abbott Laboratories' protease inhibitor Norvir. Both Norvir and Invirase have previously been approved separately to treat HIV disease. However, Invirase, the first protease inhibitor ever approved by the FDA, is rarely used in HIV therapy because in its unboosted form it fails to reach adequate levels in the bloodstream. Roche began marketing an improved version of Invirase, called Fortovase, in 1997. New studies by the company showed that a 1,000-milligram Invirase/100-milligram Norvir combination is as effective in reducing HIV viral loads as treatment with Fortovase. The medications will be dosed in five capsules taken twice per day within two hours of eating. Company officials say Invirase should not be taken without a booster dose of Norvir because the drug when used alone is ineffective in slowing or preventing the spread of HIV in the body.
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Queer Youth Negatively Affected by Anti-LGBTQ+ Laws, Debates: Trevor Project Poll
January 20 2023 5:18 PM
Emanuele Crialese on His Autobiographical Coming-of-age Trans Film, L'immensitÃ
January 19 2023 8:02 PM
CPAC's Matt Schlapp & Wife Sued By GOP Staffer For Sex Harassment, Defamation
January 19 2023 5:13 PM
'Elm Street' Star Mark Patton Hospitalized With AIDS Complications, Seeks Help
January 19 2023 9:12 AM